Identification

Name
Olopatadine
Accession Number
DB00768  (APRD00310)
Type
Small Molecule
Groups
Approved
Description

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Structure
Thumb
Synonyms
  • Olopatadin
  • Olopatadina
  • Olopatadine
  • Olopatadinum
  • Opatanol
External IDs
AL-4943A / ALO 4943 A / KW 4679
Product Ingredients
IngredientUNIICASInChI Key
Olopatadine Hydrochloride2XG66W44KF140462-76-6HVRLZEKDTUEKQH-NOILCQHBSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act Olopatadine 0.1%Solution0.1 %OphthalmicActavis Pharma Company2013-12-06Not applicableCanada
Act Olopatadine 0.2%Solution0.2 %OphthalmicActavis Pharma Company2014-02-20Not applicableCanada
Olopatadine HydrochlorideSolution / drops2 mg/mLOphthalmicSandoz2007-02-15Not applicableUs
Olopatadine HydrochlorideSolution / drops1 mg/mLOphthalmicSandoz2015-09-15Not applicableUs
Olopatadine Hydrochloride NasalSpray665 ug/1NasalPerrigo New York Inc.2015-04-01Not applicableUs
Olopatadine Ophthalmic SolutionSolution0.1 %OphthalmicBeximco Pharmaceuticals Canada LimitedNot applicableNot applicableCanada
PatadaySolution / drops2 mg/mLOphthalmicLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2012-04-032017-10-04Us
PatadaySolution0.2 %OphthalmicNovartis2011-04-14Not applicableCanada
PatadaySolution / drops2 mg/mLOphthalmicAlcon, Inc.2007-02-15Not applicableUs
PatadaySolution / drops2 mg/mLOphthalmicPhysicians Total Care, Inc.2011-01-03Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-olopatadineSolution0.2 %OphthalmicApotex Corporation2014-04-10Not applicableCanada
Apo-olopatadineSolution0.1 %OphthalmicApotex Corporation2013-07-26Not applicableCanada
Jamp-olopatadineSolution0.1 %OphthalmicJamp Pharma Corporation2017-10-06Not applicableCanada
Mint-olopatadineSolution0.1 %OphthalmicMint Pharmaceuticals Inc2014-07-29Not applicableCanada
OlopatadineSolution / drops1 mg/mLOphthalmicGolden State Medical Supply2018-01-08Not applicableUs
OlopatadineSolution / drops2 mg/mLOphthalmicAkorn2017-12-05Not applicableUs
OlopatadineSolution / drops1 mg/mLOphthalmicAkorn2017-01-10Not applicableUs
Olopatadine HydrochlorideSpray, metered665 ug/1NasalApotex Corporation2014-10-27Not applicableUs
Olopatadine HydrochlorideSolution / drops2 mg/mLOphthalmicCipla Limited2017-12-05Not applicableUs
Olopatadine HydrochlorideSolution / drops1.11 mg/mLOphthalmicNovel Laboratories, Inc.2015-12-072016-10-13Us
International/Other Brands
Alchek (Apex) / Alerchek (Indoco) / Allelock (Dae Woong) / Opatanol (Alcon) / Patanol S (Alcon)
Categories
UNII
D27V6190PM
CAS number
113806-05-6
Weight
Average: 337.4122
Monoisotopic: 337.167793607
Chemical Formula
C21H23NO3
InChI Key
JBIMVDZLSHOPLA-LSCVHKIXSA-N
InChI
InChI=1S/C21H23NO3/c1-22(2)11-5-8-18-17-7-4-3-6-16(17)14-25-20-10-9-15(12-19(18)20)13-21(23)24/h3-4,6-10,12H,5,11,13-14H2,1-2H3,(H,23,24)/b18-8-
IUPAC Name
2-[(2Z)-2-[3-(dimethylamino)propylidene]-9-oxatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3(8),4,6,11,13-hexaen-5-yl]acetic acid
SMILES
CN(C)CC\C=C1\C2=CC=CC=C2COC2=C1C=C(CC(O)=O)C=C2

Pharmacology

Indication

For the treatment of ocular itching associated with allergic conjunctivitis.

Structured Indications
Pharmacodynamics

Used to treat allergic conjunctivitis (itching eyes), olopatadine inhibits the release of histamine from mast cells. It is a relatively selective histamine H1 antagonist that inhibits the in vivo and in vitro type 1 immediate hypersensitivity reaction including inhibition of histamine induced effects on human conjunctival epithelial cells.

Mechanism of action

Olopatadine is a selective histamine H1 antagonist that binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Olopatadine is devoid of effects on alpha-adrenergic, dopamine and muscarinic type 1 and 2 receptors.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
UProtein S100-A1
antagonist
Human
UProtein S100-A12
antagonist
Human
UProtein S100-B
other/unknown
Human
UProtein S100-A13
other/unknown
Human
UProtein S100-A2
antagonist
Human
Absorption

Ophthalmic use of olopatadine usually does not produce measurable plasma concentrations.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

The mono-desmethyl and the N-oxide metabolites have been detected at low concentrations in the urine.

Route of elimination

Elimination was predominantly through renal excretion.

Half life

3 hours

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Olopatadine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 19-norandrostenedione.Experimental, Illicit
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Olopatadine.Experimental
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with 5-androstenedione.Experimental, Illicit
AbciximabOlopatadine may increase the anticoagulant activities of Abciximab.Approved
AcebutololOlopatadine may decrease the antihypertensive activities of Acebutolol.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolOlopatadine may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acetylsalicylic acid.Approved, Vet Approved
AclarubicinOlopatadine may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Olopatadine.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Aldosterone.Experimental, Investigational
AldoxorubicinOlopatadine may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alendronic acid.Approved
AliskirenOlopatadine may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Alminoprofen.Experimental
AlprenololOlopatadine may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Olopatadine.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Amcinonide.Approved
AmikacinOlopatadine may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Vet Approved
AmilorideOlopatadine may decrease the antihypertensive activities of Amiloride.Approved
AmiodaroneThe metabolism of Olopatadine can be decreased when combined with Amiodarone.Approved, Investigational
AmphetamineAmphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
AmrubicinOlopatadine may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodOlopatadine may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Anisodamine.Investigational
AnnamycinOlopatadine may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Antipyrine.Approved
Antithrombin III humanOlopatadine may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanOlopatadine may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apocynin.Investigational
ApramycinOlopatadine may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Apremilast.Approved, Investigational
AprepitantThe serum concentration of Olopatadine can be increased when it is combined with Aprepitant.Approved, Investigational
ArbekacinOlopatadine may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinOlopatadine may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanOlopatadine may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololOlopatadine may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Atamestane.Investigational
AtazanavirThe metabolism of Olopatadine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololOlopatadine may decrease the antihypertensive activities of Atenolol.Approved
AtomoxetineThe metabolism of Olopatadine can be decreased when combined with Atomoxetine.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Olopatadine.Approved
BalsalazideOlopatadine may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BecaplerminOlopatadine may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololOlopatadine may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinOlopatadine may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Olopatadine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Olopatadine.Approved
BenorilateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benoxaprofen.Withdrawn
BenzphetamineBenzphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
BenzydamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Benzydamine.Approved
Benzylpenicilloyl PolylysineOlopatadine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Olopatadine.Investigational
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Olopatadine.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Betamethasone.Approved, Vet Approved
BetaxololOlopatadine may decrease the antihypertensive activities of Betaxolol.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Olopatadine.Approved, Investigational
BevantololOlopatadine may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Olopatadine.Approved, Investigational
BisoprololOlopatadine may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinOlopatadine may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Olopatadine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololOlopatadine may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe metabolism of Olopatadine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Olopatadine can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Olopatadine.Approved
BucillamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bucillamine.Investigational
BucindololOlopatadine may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bufexamac.Experimental
BufuralolOlopatadine may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Bumadizone.Experimental
BumetanideOlopatadine may decrease the diuretic activities of Bumetanide.Approved
BupranololOlopatadine may decrease the antihypertensive activities of Bupranolol.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Olopatadine.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Olopatadine.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Olopatadine.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Olopatadine.Approved
CarbamazepineThe metabolism of Olopatadine can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carbaspirin calcium.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Olopatadine.Approved
CarprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololOlopatadine may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolOlopatadine may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Olopatadine.Approved, Investigational
CeliprololOlopatadine may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Olopatadine can be increased when it is combined with Ceritinib.Approved
CertoparinOlopatadine may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Olopatadine.Approved, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Olopatadine.Illicit, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Olopatadine.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Olopatadine.Approved
CinoxacinOlopatadine may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidOlopatadine may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClarithromycinThe metabolism of Olopatadine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Olopatadine can be decreased when combined with Clemastine.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Olopatadine.Vet Approved
CloranololOlopatadine may decrease the antihypertensive activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Olopatadine can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe metabolism of Olopatadine can be decreased when combined with Cobicistat.Approved
ColesevelamColesevelam can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Olopatadine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Olopatadine.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Cortisone acetate.Approved
CrizotinibThe metabolism of Olopatadine can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Olopatadine is combined with Curcumin.Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Olopatadine.Experimental
CyclosporineOlopatadine may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
Dabigatran etexilateOlopatadine may increase the anticoagulant activities of Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Olopatadine can be decreased when it is combined with Dabrafenib.Approved
DalteparinOlopatadine may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidOlopatadine may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanOlopatadine may increase the anticoagulant activities of Darexaban.Investigational
DarunavirThe metabolism of Olopatadine can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Olopatadine can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinOlopatadine may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeferasiroxThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Olopatadine is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Delapril is combined with Olopatadine.Experimental
DelavirdineThe metabolism of Olopatadine can be decreased when combined with Delavirdine.Approved
DesirudinOlopatadine may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Olopatadine.Approved, Investigational
DextranOlopatadine may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Olopatadine may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Olopatadine may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Olopatadine may increase the anticoagulant activities of Dextran 75.Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
DibekacinOlopatadine may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Olopatadine.Approved, Vet Approved
DicoumarolOlopatadine may increase the anticoagulant activities of Dicoumarol.Approved
DiethylpropionDiethylpropion may decrease the sedative activities of Olopatadine.Approved, Illicit
DifenpiramideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Diflunisal.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Olopatadine.Approved
DihydroergotamineThe metabolism of Olopatadine can be decreased when combined with Dihydroergotamine.Approved
DihydrostreptomycinOlopatadine may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe metabolism of Olopatadine can be decreased when combined with Diltiazem.Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Olopatadine.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Olopatadine.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Olopatadine.Approved
DoxorubicinOlopatadine may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DoxycyclineThe metabolism of Olopatadine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Olopatadine can be decreased when combined with Dronedarone.Approved
DrospirenoneOlopatadine may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Olopatadine is combined with E-6201.Investigational
Edetic AcidOlopatadine may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanOlopatadine may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Olopatadine.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Olopatadine.Approved
EnoxacinOlopatadine may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinOlopatadine may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Olopatadine.Experimental
EnzalutamideThe serum concentration of Olopatadine can be decreased when it is combined with Enzalutamide.Approved
EpanololOlopatadine may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Epirizole.Approved
EpirubicinOlopatadine may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EplerenoneOlopatadine may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Olopatadine.Approved
EquileninThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Equilin.Approved
ErythromycinThe metabolism of Olopatadine can be decreased when combined with Erythromycin.Approved, Vet Approved
EsmololOlopatadine may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone sulfate.Approved
Etacrynic acidOlopatadine may decrease the diuretic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Olopatadine.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ethenzamide.Experimental
Ethyl biscoumacetateOlopatadine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Olopatadine.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etofenamate.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Evening primrose oil.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Olopatadine is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Olopatadine.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Olopatadine.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Feprazone.Experimental
Ferulic acidOlopatadine may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Olopatadine.Approved, Investigational
FleroxacinOlopatadine may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Olopatadine.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluasterone.Investigational
FluconazoleThe metabolism of Olopatadine can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fludrocortisone.Approved
FluindioneOlopatadine may increase the anticoagulant activities of Fluindione.Investigational
FlumequineOlopatadine may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluorometholone.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Olopatadine.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Olopatadine.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Fluticasone propionate.Approved
FluvoxamineThe metabolism of Olopatadine can be decreased when combined with Fluvoxamine.Approved, Investigational
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Olopatadine.Approved, Nutraceutical, Vet Approved
FondaparinuxOlopatadine may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumOlopatadine may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Olopatadine.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Formestane.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Olopatadine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Olopatadine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Olopatadine.Approved
FosphenytoinThe metabolism of Olopatadine can be increased when combined with Fosphenytoin.Approved
FramycetinOlopatadine may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideOlopatadine may decrease the diuretic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Olopatadine can be increased when it is combined with Fusidic Acid.Approved
GabexateOlopatadine may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinOlopatadine may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinOlopatadine may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Olopatadine.Approved, Withdrawn
GemifloxacinOlopatadine may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinOlopatadine may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinOlopatadine may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AOlopatadine may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GepefrineGepefrine may decrease the sedative activities of Olopatadine.Experimental
GPX-150Olopatadine may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinOlopatadine may increase the neuroexcitatory activities of Grepafloxacin.Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Olopatadine is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Olopatadine is combined with HE3286.Investigational
HeparinOlopatadine may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Higenamine.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Olopatadine.Approved, Investigational
HydralazineOlopatadine may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Olopatadine.Approved, Investigational
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Olopatadine.Approved
Hygromycin BOlopatadine may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.Approved, Investigational
IbuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Olopatadine is combined with Icatibant.Approved
IdarubicinOlopatadine may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdelalisibThe metabolism of Olopatadine can be decreased when combined with Idelalisib.Approved
IdraparinuxOlopatadine may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.Approved, Investigational
ImatinibThe metabolism of Olopatadine can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Olopatadine.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Olopatadine.Approved
IndenololOlopatadine may decrease the antihypertensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Olopatadine can be decreased when combined with Indinavir.Approved
IndobufenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Olopatadine.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Indoprofen.Withdrawn
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Olopatadine.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Olopatadine.Approved, Investigational
IsavuconazoniumThe metabolism of Olopatadine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsepamicinOlopatadine may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Isoxicam.Withdrawn
IsradipineThe metabolism of Olopatadine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Olopatadine is combined with Istaroxime.Investigational
ItraconazoleThe metabolism of Olopatadine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Olopatadine can be increased when it is combined with Ivacaftor.Approved
KanamycinOlopatadine may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Kebuzone.Experimental
KetoconazoleThe metabolism of Olopatadine can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Olopatadine.Approved
LabetalolOlopatadine may decrease the antihypertensive activities of Labetalol.Approved
LandiololOlopatadine may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Olopatadine.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Olopatadine.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Leflunomide.Approved, Investigational
LepirudinOlopatadine may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanOlopatadine may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololOlopatadine may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinOlopatadine may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Olopatadine.Approved, Investigational
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Olopatadine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Olopatadine.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Olopatadine.Approved
LonazolacThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lonazolac.Experimental
LopinavirThe metabolism of Olopatadine can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lornoxicam.Approved, Investigational
LorpiprazoleThe serum concentration of Olopatadine can be increased when it is combined with Lorpiprazole.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Olopatadine.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loteprednol.Approved
LovastatinThe metabolism of Olopatadine can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Olopatadine.Approved, Investigational
LuliconazoleThe serum concentration of Olopatadine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Olopatadine can be increased when combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Olopatadine.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Olopatadine.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Olopatadine is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mefenamic acid.Approved
MelagatranOlopatadine may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Olopatadine is combined with Meloxicam.Approved, Vet Approved
MephedroneMephedrone may decrease the sedative activities of Olopatadine.Investigational
MephentermineMephentermine may decrease the sedative activities of Olopatadine.Approved
MepindololOlopatadine may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineOlopatadine may increase the nephrotoxic activities of Mesalazine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.Investigational, Withdrawn
MethamphetamineMethamphetamine may decrease the sedative activities of Olopatadine.Approved, Illicit
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Olopatadine.Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Olopatadine.Experimental
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Olopatadine.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methylprednisolone.Approved, Vet Approved
MetipranololOlopatadine may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Olopatadine.Approved
MetoprololOlopatadine may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MetrizamideOlopatadine may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MicronomicinOlopatadine may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidomafetamineMidomafetamine may decrease the sedative activities of Olopatadine.Experimental, Illicit, Investigational
MifepristoneThe serum concentration of Olopatadine can be increased when it is combined with Mifepristone.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Olopatadine.Approved
MitotaneThe serum concentration of Olopatadine can be decreased when it is combined with Mitotane.Approved
MizoribineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mizoribine.Investigational
MMDAMMDA may decrease the sedative activities of Olopatadine.Experimental, Illicit
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Olopatadine.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Olopatadine.Approved
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Olopatadine.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Olopatadine.Approved
NadololOlopatadine may decrease the antihypertensive activities of Nadolol.Approved
NadroparinOlopatadine may increase the anticoagulant activities of Nadroparin.Approved
NafamostatOlopatadine may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Olopatadine.Approved
Nalidixic AcidOlopatadine may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Olopatadine is combined with NCX 1022.Investigational
NeamineOlopatadine may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololOlopatadine may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Olopatadine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Olopatadine can be decreased when combined with Nelfinavir.Approved
NemonoxacinOlopatadine may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinOlopatadine may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Olopatadine.Approved
NetilmicinOlopatadine may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NetupitantThe serum concentration of Olopatadine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Olopatadine can be increased when combined with Nevirapine.Approved
NifenazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Niflumic Acid.Approved
NilotinibThe metabolism of Olopatadine can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Nitroaspirin.Investigational
NorfloxacinOlopatadine may increase the neuroexcitatory activities of Norfloxacin.Approved
OlaparibThe metabolism of Olopatadine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Olopatadine.Approved, Investigational
OlsalazineOlopatadine may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of can be d when Olopatadine is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Olopatadine.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Orgotein.Vet Approved
OsimertinibThe serum concentration of Olopatadine can be increased when it is combined with Osimertinib.Approved
OtamixabanOlopatadine may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxaprozin.Approved
Oxolinic acidOlopatadine may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOlopatadine may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Oxyphenbutazone.Approved, Withdrawn
PalbociclibThe serum concentration of Olopatadine can be increased when it is combined with Palbociclib.Approved
PamidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parecoxib.Approved
ParomomycinOlopatadine may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Parthenolide.Investigational
PazufloxacinOlopatadine may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinOlopatadine may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololOlopatadine may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateOlopatadine may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe metabolism of Olopatadine can be increased when combined with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Olopatadine.Approved
PhenindioneOlopatadine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe metabolism of Olopatadine can be increased when combined with Phenobarbital.Approved
PhenprocoumonOlopatadine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenterminePhentermine may decrease the sedative activities of Olopatadine.Approved, Illicit
PhenylbutazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Phenylbutazone.Approved, Vet Approved
PhenytoinThe metabolism of Olopatadine can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Olopatadine.Approved, Investigational
PindololOlopatadine may decrease the antihypertensive activities of Pindolol.Approved
Pipemidic acidOlopatadine may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinOlopatadine may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideOlopatadine may decrease the diuretic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirfenidone.Approved, Investigational
Piromidic acidOlopatadine may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Olopatadine.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pirprofen.Experimental
Platelet Activating FactorOlopatadine may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinOlopatadine may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinOlopatadine may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Olopatadine.Approved
PosaconazoleThe metabolism of Olopatadine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololOlopatadine may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Olopatadine.Approved
PranoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednicarbate.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Pregnenolone.Experimental, Investigational
PrimidoneThe metabolism of Olopatadine can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Olopatadine can be increased when it is combined with Probenecid.Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propacetamol.Approved, Investigational
PropranololOlopatadine may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Olopatadine.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Olopatadine.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Olopatadine.Vet Approved
Protein COlopatadine may increase the anticoagulant activities of Protein C.Approved
Protein S humanOlopatadine may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeOlopatadine may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinOlopatadine may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Olopatadine.Approved
PTC299The risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299.Investigational
PuromycinOlopatadine may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Olopatadine.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Olopatadine.Approved
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Olopatadine.Approved
RanolazineThe metabolism of Olopatadine can be decreased when combined with Ranolazine.Approved, Investigational
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Olopatadine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinOlopatadine may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinOlopatadine may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RifabutinThe metabolism of Olopatadine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Olopatadine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Olopatadine can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Risedronate.Approved, Investigational
RitobegronRitobegron may decrease the sedative activities of Olopatadine.Investigational
RivaroxabanOlopatadine may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Olopatadine.Investigational, Withdrawn
RosoxacinOlopatadine may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RucaparibThe metabolism of Olopatadine can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinOlopatadine may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinOlopatadine may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Olopatadine.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Olopatadine.Experimental
SaquinavirThe metabolism of Olopatadine can be decreased when combined with Saquinavir.Approved, Investigational
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Olopatadine.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Olopatadine.Approved
SemapimodThe risk or severity of adverse effects can be increased when Olopatadine is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Olopatadine is combined with Serrapeptase.Investigational
SildenafilThe metabolism of Olopatadine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Olopatadine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Olopatadine can be increased when it is combined with Simeprevir.Approved
SisomicinOlopatadine may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinOlopatadine may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Olopatadine.Approved
SotalolOlopatadine may decrease the antihypertensive activities of Sotalol.Approved
SP1049COlopatadine may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinOlopatadine may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinOlopatadine may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Olopatadine.Approved
SRT501The risk or severity of adverse effects can be increased when Olopatadine is combined with SRT501.Investigational
St. John's WortThe serum concentration of Olopatadine can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Olopatadine can be increased when it is combined with Stiripentol.Approved
StreptomycinOlopatadine may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinOlopatadine may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Sulfasalazine.Approved
SulfisoxazoleThe metabolism of Olopatadine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Olopatadine.Approved
SulodexideOlopatadine may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Olopatadine.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Suxibuzone.Experimental
TacrolimusOlopatadine may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Olopatadine.Approved
TalinololOlopatadine may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Olopatadine.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Olopatadine.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Olopatadine is combined with Technetium Tc-99m medronate.Approved
TelaprevirThe metabolism of Olopatadine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Olopatadine can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Olopatadine.Approved, Investigational
TemafloxacinOlopatadine may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Olopatadine.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Olopatadine.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tepoxalin.Vet Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Teriflunomide.Approved
TertatololOlopatadine may decrease the antihypertensive activities of Tertatolol.Experimental
ThalidomideOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiaprofenic acid.Approved
TiclopidineThe metabolism of Olopatadine can be decreased when combined with Ticlopidine.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololOlopatadine may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tixocortol.Approved, Withdrawn
TobramycinOlopatadine may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TocilizumabThe serum concentration of Olopatadine can be decreased when it is combined with Tocilizumab.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tolfenamic Acid.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Olopatadine.Approved
TorasemideOlopatadine may decrease the diuretic activities of Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Olopatadine.Approved
TranilastThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tranilast.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Olopatadine.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Olopatadine.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triamcinolone.Approved, Vet Approved
TriamtereneOlopatadine may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Olopatadine.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Olopatadine is combined with Triptolide.Investigational
TrovafloxacinOlopatadine may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinOlopatadine may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Olopatadine is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Olopatadine.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Olopatadine.Investigational, Withdrawn
ValrubicinOlopatadine may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Olopatadine.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Olopatadine.Approved
VemurafenibThe serum concentration of Olopatadine can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Olopatadine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Olopatadine can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Olopatadine can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinOlopatadine may increase the anticoagulant activities of Warfarin.Approved
XimelagatranOlopatadine may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zaltoprofen.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Olopatadine.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Olopatadine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe risk or severity of adverse effects can be increased when Zofenopril is combined with Olopatadine.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Olopatadine is combined with Zomepirac.Withdrawn
Zoptarelin doxorubicinOlopatadine may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinOlopatadine may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

Synthesis Reference

Thomas Bader, Hans-Ulrich Bichsel, Bruno Gilomen, Imelda Meyer-Wilmes, Mark Sundermeier, "Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof." U.S. Patent US20070232814, issued October 04, 2007.

US20070232814
General References
  1. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  2. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  3. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  4. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  5. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
External Links
Human Metabolome Database
HMDB0014906
KEGG Compound
C07789
PubChem Compound
5281071
PubChem Substance
46506025
ChemSpider
4444528
BindingDB
50002096
ChEMBL
CHEMBL1189432
Therapeutic Targets Database
DAP001062
PharmGKB
PA450698
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Olopatadine
ATC Codes
S01GX09 — OlopatadineR01AC08 — Olopatadine
AHFS Codes
  • 52:02.00 — Antiallergic Agents
  • 04:00.00 — Antihistamine Drugs
FDA label
Download (114 KB)
MSDS
Download (57.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableConjunctivitis, Seasonal Allergic1
2CompletedTreatmentConjunctivitis, Seasonal Allergic2
2RecruitingTreatmentConjunctivitis, Seasonal Allergic1
2TerminatedTreatmentSeasonal Allergic Conjunctivitis to Ragweed1
3CompletedNot AvailableConjunctivitis, Seasonal Allergic2
3CompletedPreventionConjunctivitis, Seasonal Allergic1
3CompletedTreatmentConjunctivitis, Seasonal Allergic7
3CompletedTreatmentConjunctivitis, Seasonal Allergic / Rhinitis, Allergic, Seasonal1
3RecruitingTreatmentRhinitis, Allergic, Seasonal1
3SuspendedTreatmentConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableConjunctivitis, Seasonal Allergic1
4CompletedNot AvailableSeasonal Allergic Rhinitis (SAR)1
4CompletedDiagnosticConjunctivitis, Seasonal Allergic2
4CompletedPreventionConjunctivitis, Seasonal Allergic1
4CompletedTreatmentConjunctivitis, Seasonal Allergic10
4CompletedTreatmentPerennial Allergic Rhinitis (PAR)1
4RecruitingTreatmentConjunctivitis, Seasonal Allergic / Conjunctivitis, Vernal1
4WithdrawnTreatmentAllergic Rhinitis (AR)1
4WithdrawnTreatmentConjunctivitis, Seasonal Allergic1
Not AvailableCompletedTreatmentEye Allergies1
Not AvailableUnknown StatusBasic ScienceAllergic Eye Disease1

Pharmacoeconomics

Manufacturers
  • Alcon inc
  • Alcon laboratories inc
  • Alcon Laboratories, Inc.
Packagers
Dosage forms
FormRouteStrength
SolutionOphthalmic0.1 %
SolutionOphthalmic0.2 %
SolutionOphthalmic2 mg/mL
Solution / dropsOphthalmic1 mg/mL
Solution / dropsOphthalmic1.11 mg/mL
Spray, meteredNasal665 ug/100uL
SprayNasal665 ug/1
Solution / dropsOphthalmic2 mg/mL
Spray, meteredNasal600 ug/1
Spray, meteredNasal665 ug/1
LiquidOphthalmic0.1 %
SolutionOphthalmic0.7 %
SolutionOphthalmic7 mg/mL
Prices
Unit descriptionCostUnit
Patanol 0.1% Solution 5ml Bottle111.2USD bottle
Pataday 0.2% eye drops52.98USD ml
Patanol 0.1% eye drops21.38USD ml
Patanase 0.6% nasal spray3.83USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5116863No1993-12-182010-12-18Us
CA2195094No2002-02-262016-05-03Canada
CA1337603No1995-11-212012-11-21Canada
US6995186Yes2004-05-122024-05-12Us
US7402609Yes2002-12-192022-12-19Us
US8399508Yes2003-03-172023-03-17Us
US7977376Yes2003-08-022023-08-02Us
US8791154No2012-05-192032-05-19Us
US5641805Yes1995-12-062015-12-06Us
US9533053No2012-05-192032-05-19Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248 °CNot Available
water solubilitySolubleNot Available
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0313 mg/mLALOGPS
logP3.99ALOGPS
logP0.75ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.78ChemAxon
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area49.77 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.55 m3·mol-1ChemAxon
Polarizability37.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9747
Blood Brain Barrier+0.6925
Caco-2 permeable+0.7249
P-glycoprotein substrateSubstrate0.8607
P-glycoprotein inhibitor IInhibitor0.5948
P-glycoprotein inhibitor IINon-inhibitor0.8196
Renal organic cation transporterInhibitor0.5413
CYP450 2C9 substrateNon-substrate0.7691
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7242
CYP450 1A2 substrateInhibitor0.7906
CYP450 2C9 inhibitorNon-inhibitor0.8316
CYP450 2D6 inhibitorInhibitor0.6567
CYP450 2C19 inhibitorNon-inhibitor0.8466
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8676
Ames testNon AMES toxic0.8032
CarcinogenicityNon-carcinogens0.8499
BiodegradationNot ready biodegradable0.6088
Rat acute toxicity2.7626 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8082
hERG inhibition (predictor II)Inhibitor0.5
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-8e3ac3f01c9b0f33191f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0007-0090000000-ff327751665292322357
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-00ke-0190000000-4ee44c0a1808c8f38f5f
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0490000000-af62db4d573fa623449b
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0690000000-855734373da970ef9009
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014l-0970000000-10c3777ced99134b4960
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0009000000-edd957bf788fa0da1cd5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0019000000-76019801740d70094185
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kk-0593000000-0fb46422a259d1710df5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-016s-0690000000-d2686bcc07833ec6a7c5
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fw9-0690000000-20403692a9e2a6948063
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0009000000-e2c029010aa3133274f8
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-1239000000-a4a1f419cb7782a025ae
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-015a-4890000000-5408d5e1274f9ec8ab42
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4970000000-5d3cad1a8e8d0b931c62
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00lu-4960000000-d57d90bc4e9b3f57c2fa
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0frx-5960000000-9b3e25cd1765878b5709
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0469000000-a0b3c5cdd43e637acdec

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzoxepines. These are compounds containing a dibenzoxepine moiety, which consists of two benzene connected by an oxazepine ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzoxepines
Sub Class
Dibenzoxepines
Direct Parent
Dibenzoxepines
Alternative Parents
Alkyl aryl ethers / Benzenoids / Trialkylamines / Amino acids / Oxacyclic compounds / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
show 1 more
Substituents
Dibenzoxepine / Alkyl aryl ether / Benzenoid / Amino acid or derivatives / Amino acid / Tertiary aliphatic amine / Tertiary amine / Carboxylic acid derivative / Carboxylic acid / Oxacycle
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Tamura T, Masaki S, Ohmori K, Karasawa A: Effect of olopatadine and other histamine H1 receptor antagonists on the skin inflammation induced by repeated topical application of oxazolone in mice. Pharmacology. 2005 Dec;75(1):45-52. Epub 2005 Jun 7. [PubMed:15942272]
  2. Ohmori K, Hayashi K, Kaise T, Ohshima E, Kobayashi S, Yamazaki T, Mukouyama A: Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride, a new antiallergic drug. Jpn J Pharmacol. 2002 Apr;88(4):379-97. [PubMed:12046981]
  3. Yanni JM, Stephens DJ, Miller ST, Weimer LK, Graff G, Parnell D, Lang LS, Spellman JM, Brady MT, Gamache DA: The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent. J Ocul Pharmacol Ther. 1996 Winter;12(4):389-400. [PubMed:8951675]
  4. Ohmori K, Hasegawa K, Tamura T, Miyake K, Matsubara M, Masaki S, Karasawa A, Urayama N, Horikoshi K, Kajita J, Hasegawa M, Taniguchi K, Komada T, Kawamoto Y: Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung. 2004;54(12):809-29. [PubMed:15646365]
  5. Ohmori K, Ikemura T, Kobayashi H, Mukouyama A: [Pharmacological, pharmacokinetic and clinical properties of olopatadine hydrochloride' (olopatadine), an antiallergic drug]. Nihon Yakurigaku Zasshi. 2001 Jul;118(1):51-8. [PubMed:11496828]
  6. Roland PS, Ryan MW, Wall GM: Olopatadine nasal spray for the treatment of seasonal allergic rhinitis in patients aged 6 years and older. Expert Opin Pharmacother. 2010 Jun;11(9):1559-67. doi: 10.1517/14656566.2010.485609. [PubMed:20482305]
  7. Kaliner MA, Oppenheimer J, Farrar JR: Comprehensive review of olopatadine: the molecule and its clinical entities. Allergy Asthma Proc. 2010 Mar-Apr;31(2):112-9. doi: 10.2500/aap.2010.31.3317. [PubMed:20406593]
  8. Roland PS, Marple BF, Wall GM: Olopatadine nasal spray for the treatment of allergic rhinitis. Expert Rev Clin Immunol. 2010 Mar;6(2):197-204. [PubMed:20402382]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
S100 protein binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100A1
Uniprot ID
P23297
Uniprot Name
Protein S100-A1
Molecular Weight
10545.755 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Zinc ion binding
Specific Function
S100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response. Its proinflammatory activity involves recruitme...
Gene Name
S100A12
Uniprot ID
P80511
Uniprot Name
Protein S100-A12
Molecular Weight
10574.975 Da
References
  1. Kishimoto K, Kaneko S, Ohmori K, Tamura T, Hasegawa K: Olopatadine suppresses the migration of THP-1 monocytes induced by S100A12 protein. Mediators Inflamm. 2006;2006(1):42726. [PubMed:16864903]
  2. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Weakly binds calcium but binds zinc very tightly-distinct binding sites with different affinities exist for both ions on each monomer. Physiological concentrations of potassium ion antagonize the b...
Gene Name
S100B
Uniprot ID
P04271
Uniprot Name
Protein S100-B
Molecular Weight
10712.985 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Zinc ion binding
Specific Function
Plays a role in the export of proteins that lack a signal peptide and are secreted by an alternative pathway. Binds two calcium ions per subunit. Binds one copper ion. Binding of one copper ion doe...
Gene Name
S100A13
Uniprot ID
Q99584
Uniprot Name
Protein S100-A13
Molecular Weight
11471.095 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Identical protein binding
Specific Function
May function as calcium sensor and modulator, contributing to cellular calcium signaling. May function by interacting with other proteins, such as TPR-containing proteins, and indirectly play a rol...
Gene Name
S100A2
Uniprot ID
P29034
Uniprot Name
Protein S100-A2
Molecular Weight
11116.695 Da
References
  1. Okada M, Tokumitsu H, Kubota Y, Kobayashi R: Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: identification of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun. 2002 Apr 12;292(4):1023-30. [PubMed:11944917]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on January 23, 2018 12:13